News | EP Lab | May 20, 2020

Biotronik Partners With Acutus Medical to Offer More Efficient Arrhythmia Diagnosis and Treatment

New alliance maps new path way in electrophysiology mapping, ablation 

he Actus AcQMap EP 3-D mapping catheter used  to speed  electromapping and procedure times.

he Actus AcQMap EP 3-D mapping catheter used  to speed  electromapping and procedure times.

May 20, 2020 — Acutus Medical and Biotronik announced a new alliance to provide a comprehensive portfolio of electrophysiology, mapping, ablation and accessory products for catheter-based treatment of cardiac arrhythmias across select markets, including Europe and Asia.

At the center of the new Biotronik/Acutus Alliance for Electrophysiology lies the paradigm-shifting Acutus AcQMap system with SuperMap multi-mode mapping capabilities. The AcQMap system is the only commercially available non-contact mapping system that can quickly and reliably map both stable and unstable rhythms, allowing electrophysiologists to see changes in conduction during the procedure and arming them with an optimal solution to better customize therapy. 

The system optimizes visibility and helps to map and guide the treatment of any arrhythmia – from simple to highly complex – in under three minutes. Under terms of the agreement, Acutus expects to market under private label a range of Biotronik EP ablation catheters and diagnostic/accessory products to most major international markets, providing a full suite of leading products for the electrophysiologist (EP).

One of the objectives of the alliance is to optimize care for arrhythmia patients with an array of devices and monitors that would be linked digitally. This could happen through Biotronik's Home Monitoring network with Acutus' system in order to enable fully automatic transmission of real-time data between patients, physicians and technicians. A secure digital network across both cardiac rhythm management (CRM) and EP mapping and ablation devices has the potential to optimize care by providing physicians with high levels of connectivity and remote monitoring benefits before, during and after ablation, follow-up visits and other episodes of care, including digitally supported telemedicine.

Studies have shown that proactive monitoring through Home Monitoring helps to significantly reduce hospitalization, stroke and mortality.[1,2] In addition, connecting physicians and health systems worldwide with efficient and cost-effective diagnostics, therapies and follow-up across both CRM and EP portfolios would help to modernize workflows and boost outcomes for patients.

"Healthcare systems around the world are facing continuous pressure to provide more targeted care for patients with better outcomes and reduced costs," said President and CEO of Acutus Medical, Vince Burgess. "We are at the forefront of equipping electrophysiologists with the technology they need to deliver advanced and individualized ablation therapy – more efficiently. We believe this International Alliance has the potential to vault Acutus to the forefront of this important market."

"As arrhythmias become more common, unprecedented access to real-time data will be integral to improving diagnosis and care," said Segment Head of EP and sensors at Biotronik, Dr. Hans-Juergen Wildau. "We believe pairing Biotronik's cardiac monitoring portfolio with Acutus' innovative mapping technology will give EP specialists the edge in therapy guidance systems."

For more information: www.acutusmedical.com

References:
1. Hindricks et al. European Heart Journal 2017, 38, 1749–1755.
2. Mabo P et al. European Heart Journal. 2012, 33.

Related Content

The SERF VT EFS is a groundbreaking, single-arm observational study designed to evaluate the safety and effectiveness of the Thermedical Durablate catheter to treat VT. #HRS20 #HRS2020 #heartrhythm2020
News | Ablation Systems | May 08, 2020
May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SER
The Affera Inc. pulsed field (PF) energy radiofrequency ablation system. First-in-human trial shows new point-by-point approach provides increased flexibility and efficiency for physicians treating arrhythmia patients. #HRS #HRS2020 #HRS20 #heartrhythm20

The Affera Inc. pulsed field (PF) energy radiofrequency ablation system.

Feature | Ablation Systems | May 08, 2020
May 8, 2020 — A new clinical trial effectively uses pulsed field (PF) energy to treat patients with persistent or par
Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Ablation Systems | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically
Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
Ablation Reduces Risk of Dementia in Patients With AFib and Carotid Artery Disease
News | Ablation Systems | May 08, 2019
Even though many medical practitioners may opt not to perform procedures on higher-risk patients, new research finds it...